Week | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
---|---|---|---|---|---|---|---|---|---|
Baseline | Treatment period (4 to 8 session) | Follow-up | |||||||
Sign informed consent | √ | ||||||||
TNSS | √ | √ | √ | √ | √ | ||||
TNNSS | √ | √ | √ | √ | √ | ||||
Physical sign | √ | √ | √ | √ | √ | ||||
RQLQ score | √ | √ | √ | √ | √ | ||||
IgE level | √ | √ | |||||||
Eosinophil count | √ | √ | |||||||
Number of days with moderate-severe PER in the last month | √ | √ | |||||||
Allergen test | √ | ||||||||
Randomization | √ | ||||||||
Onset time | √ | √ | √ | √ | |||||
Duration of effectiveness in every session | √ | √ | √ | √ | |||||
Waiting time | √ | √ | √ | √ | |||||
Adverse event | √ | √ | √ | √ |